uprifosbuvir + itraconazole

**Uprifosbuvir + itraconazole** is an investigational combination of two pharmaceutical drugs: uprifosbuvir, a uridine nucleotide analog prodrug and direct-acting antiviral that inhibits the hepatitis C virus (HCV) NS5B RNA polymerase[2][4][6], and itraconazole, a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, disrupting ergosterol synthesis[5]. Uprifosbuvir is under development for chronic hepatitis C infection, while itraconazole is widely used to treat fungal infections. There is no evidence this combination has been clinically tested or marketed as a unique product; no studies or clinical guidelines address this exact pairing. No synergistic mechanisms are known between uprightfosbuvir (for viral hepatitis C) and itraconazole (for fungal infections), and no specific development or regulatory status for this drug pairing is found.